MADRIGAL PHARMACEUTICALS, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $219.59 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2023-11-06
- MADRIGAL PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2023-09-30 was $119.39M, a 50.43% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2023-06-30 was $88.21M, a 10.23% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2023-03-31 was $11.99M, a 87.18% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2022-12-31 was $79.20M, a 12.33% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $350.38M, a 9.99% decline from fiscal 2021.
- MADRIGAL PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2021 was $389.27M, a 20.47% decline from fiscal 2020.
- MADRIGAL PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2020 was $489.46M, a 24.72% decline from fiscal 2019.
- MADRIGAL PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2019 was $650.18M, a 177.50% increase from fiscal 2018.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-09-30 | $119.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $207.60M derived: sum of 2 quarters · filed 2023-11-06 | $219.59M 10-Q · filed 2023-11-06 | $298.80M derived: sum of 4 quarters · filed 2023-11-06 | ||
| 2023-06-30 | $88.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $100.20M 10-Q · filed 2023-08-08 | $179.41M derived: sum of 3 quarters · filed 2023-08-08 | $258.77M derived: sum of 4 quarters · filed 2023-11-06 | ||
| 2023-03-31 | $11.99M 10-Q · filed 2023-05-09 | $91.19M derived: sum of 2 quarters · filed 2023-05-09 | $170.56M derived: sum of 3 quarters · filed 2023-11-06 | $268.83M derived: sum of 4 quarters · filed 2023-11-06 | ||
| 2022-12-31 | $79.20M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-03 | $158.57M derived: sum of 2 quarters · filed 2023-11-06 | $256.84M derived: sum of 3 quarters · filed 2023-11-06 | $350.38M 10-K/A · filed 2023-03-03 | ||
| 2022-09-30 | $79.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $177.63M derived: sum of 2 quarters · filed 2023-11-06 | $271.18M 10-Q · filed 2023-11-06 | $341.69M derived: sum of 4 quarters · filed 2023-11-06 | ||
| 2022-06-30 | $98.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $191.81M 10-Q · filed 2023-08-08 | $262.32M derived: sum of 3 quarters · filed 2023-08-08 | $417.76M derived: sum of 4 quarters · filed 2023-08-08 | ||
| 2022-03-31 | $93.55M 10-Q · filed 2023-05-09 | $164.05M derived: sum of 2 quarters · filed 2023-05-09 | $319.49M derived: sum of 3 quarters · filed 2023-05-09 | $422.52M derived: sum of 4 quarters · filed 2023-05-09 | ||
| 2021-12-31 | $70.50M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-03 | $225.95M derived: sum of 2 quarters · filed 2023-03-03 | $328.97M derived: sum of 3 quarters · filed 2023-03-03 | $389.27M 10-K/A · filed 2023-03-03 | ||
| 2021-09-30 | $155.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $258.47M derived: sum of 2 quarters · filed 2022-11-03 | $318.77M 10-Q · filed 2022-11-03 | $430.14M derived: sum of 4 quarters · filed 2023-03-03 | ||
| 2021-06-30 | $103.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $163.33M 10-Q · filed 2022-08-04 | $274.70M derived: sum of 3 quarters · filed 2023-03-03 | $428.77M derived: sum of 4 quarters · filed 2023-03-03 | ||
| 2021-03-31 | $60.30M 10-Q · filed 2022-05-09 | $171.67M derived: sum of 2 quarters · filed 2023-03-03 | $325.74M derived: sum of 3 quarters · filed 2023-03-03 | $440.34M derived: sum of 4 quarters · filed 2023-03-03 | ||
| 2020-12-31 | $111.37M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-03 | $265.44M derived: sum of 2 quarters · filed 2023-03-03 | $380.04M derived: sum of 3 quarters · filed 2023-03-03 | $489.46M 10-K/A · filed 2023-03-03 | ||
| 2020-09-30 | $154.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $268.67M derived: sum of 2 quarters · filed 2021-11-04 | $378.09M 10-Q · filed 2021-11-04 | $559.95M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-06-30 | $114.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $224.01M 10-Q · filed 2021-08-05 | $405.87M derived: sum of 3 quarters · filed 2022-02-24 | $575.09M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-03-31 | $109.42M 10-Q · filed 2021-05-06 | $291.28M derived: sum of 2 quarters · filed 2022-02-24 | $460.50M derived: sum of 3 quarters · filed 2022-02-24 | $589.22M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $181.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $351.08M derived: sum of 2 quarters · filed 2022-02-24 | $479.80M derived: sum of 3 quarters · filed 2022-02-24 | $650.18M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $169.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $297.94M derived: sum of 2 quarters · filed 2020-11-05 | $468.32M 10-Q · filed 2020-11-05 | $582.74M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-06-30 | $128.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $299.10M 10-Q · filed 2020-08-06 | $413.52M derived: sum of 3 quarters · filed 2021-02-25 | $464.57M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-03-31 | $170.39M 10-Q · filed 2020-05-07 | $284.81M derived: sum of 2 quarters · filed 2021-02-25 | $335.86M derived: sum of 3 quarters · filed 2021-02-25 | $384.62M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $114.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $165.47M derived: sum of 2 quarters · filed 2021-02-25 | $214.23M derived: sum of 3 quarters · filed 2021-02-25 | $234.30M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $51.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $99.81M derived: sum of 2 quarters · filed 2019-11-06 | $119.89M 10-Q · filed 2019-11-06 | $161.27M derived: sum of 4 quarters · filed 2020-02-26 | ||
| 2018-06-30 | $48.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $68.83M 10-Q · filed 2019-08-07 | $110.22M derived: sum of 3 quarters · filed 2020-02-26 | $97.13M derived: sum of 4 quarters · filed 2020-02-26 | ||
| 2018-03-31 | $20.07M 10-Q · filed 2019-05-08 | $61.46M derived: sum of 2 quarters · filed 2020-02-26 | $48.37M derived: sum of 3 quarters · filed 2020-02-26 | $56.84M derived: sum of 4 quarters · filed 2020-02-26 | ||
| 2017-12-31 | $41.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $28.30M derived: sum of 2 quarters · filed 2020-02-26 | $36.77M derived: sum of 3 quarters · filed 2020-02-26 | $48.33M 10-K · filed 2020-02-26 | ||
| 2017-09-30 | -$13.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$4.62M derived: sum of 2 quarters · filed 2018-11-06 | $6.94M 10-Q · filed 2018-11-06 | $24.43M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2017-06-30 | $8.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $20.03M 10-Q · filed 2018-08-07 | $37.52M derived: sum of 3 quarters · filed 2019-02-27 | $5.27M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2017-03-31 | $11.56M 10-Q · filed 2018-05-08 | $29.05M derived: sum of 2 quarters · filed 2019-02-27 | -$3.20M derived: sum of 3 quarters · filed 2019-02-27 | $6.03M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2016-12-31 | $17.48M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$14.76M derived: sum of 2 quarters · filed 2019-02-27 | -$5.54M derived: sum of 3 quarters · filed 2019-02-27 | $26.06M 10-K · filed 2019-02-27 | $26.06M 10-K · filed 2017-03-31 | |
| 2016-09-30 | -$32.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$23.02M derived: sum of 2 quarters · filed 2017-11-09 | $8.58M 10-Q · filed 2017-11-09 | $8.58M 10-Q · filed 2016-11-14 | $44.34M derived: sum of 4 quarters · filed 2017-11-09 | |
| 2016-06-30 | $9.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-20 | $40.83M 10-Q · filed 2016-07-20 | $76.58M derived: sum of 3 quarters · filed 2016-07-20 | $113.77M derived: sum of 4 quarters · filed 2016-07-20 | ||
| 2016-03-31 | $31.60M 10-Q · filed 2016-05-10 | $67.36M derived: sum of 2 quarters · filed 2016-05-10 | $104.55M derived: sum of 3 quarters · filed 2016-05-10 | $131.79M derived: sum of 4 quarters · filed 2016-07-20 | ||
| 2015-12-31 | $35.76M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $72.94M derived: sum of 2 quarters · filed 2016-03-15 | $100.19M derived: sum of 3 quarters · filed 2016-07-20 | $137.19M 10-K · filed 2016-03-15 | ||
| 2015-09-30 | $37.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $64.43M derived: sum of 2 quarters · filed 2016-07-20 | $101.43M 10-Q · filed 2015-11-05 | $125.90M derived: sum of 4 quarters · filed 2016-07-20 | ||
| 2015-06-30 | $27.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-20 | $64.25M 10-Q · filed 2016-07-20 | $88.71M derived: sum of 3 quarters · filed 2016-07-20 | $103.96M derived: sum of 4 quarters · filed 2016-07-20 | ||
| 2015-03-31 | $37.00M 10-Q · filed 2016-05-10 | $61.46M derived: sum of 2 quarters · filed 2016-05-10 | $76.71M derived: sum of 3 quarters · filed 2016-05-10 | $102.38M derived: sum of 4 quarters · filed 2016-05-10 | ||
| 2014-12-31 | $24.46M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $39.71M derived: sum of 2 quarters · filed 2016-03-15 | $65.38M derived: sum of 3 quarters · filed 2016-03-15 | $85.15M 10-K · filed 2016-03-15 | ||
| 2014-09-30 | $15.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $40.92M derived: sum of 2 quarters · filed 2015-11-05 | $60.69M 10-Q · filed 2015-11-05 | $88.59M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-06-30 | $25.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $45.44M 10-Q · filed 2015-08-06 | $73.34M derived: sum of 3 quarters · filed 2016-03-15 | $91.75M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-03-31 | $19.77M 10-Q · filed 2015-05-07 | $47.67M derived: sum of 2 quarters · filed 2016-03-15 | $66.08M derived: sum of 3 quarters · filed 2016-03-15 | $91.08M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2013-12-31 | $27.90M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $46.31M derived: sum of 2 quarters · filed 2016-03-15 | $71.32M derived: sum of 3 quarters · filed 2016-03-15 | $90.27M 10-K · filed 2016-03-15 | ||
| 2013-09-30 | $18.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $43.42M derived: sum of 2 quarters · filed 2014-11-06 | $62.37M 10-Q · filed 2014-11-06 | $73.12M derived: sum of 4 quarters · filed 2015-03-12 | ||
| 2013-06-30 | $25.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | $43.96M 10-Q · filed 2014-08-06 | $54.71M derived: sum of 3 quarters · filed 2015-03-12 | $71.21M derived: sum of 4 quarters · filed 2015-03-12 | ||
| 2013-03-31 | $18.95M 10-Q · filed 2014-05-08 | $29.70M derived: sum of 2 quarters · filed 2015-03-12 | $46.20M derived: sum of 3 quarters · filed 2015-03-12 | $49.90M derived: sum of 4 quarters · filed 2015-03-12 | ||
| 2012-12-31 | $10.75M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $27.25M derived: sum of 2 quarters · filed 2015-03-12 | $30.95M derived: sum of 3 quarters · filed 2015-03-12 | $40.59M 10-K · filed 2015-03-12 | ||
| 2012-09-30 | $16.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-04 | $20.20M derived: sum of 2 quarters · filed 2013-11-04 | $29.84M 10-Q · filed 2013-11-04 | $53.95M derived: sum of 4 quarters · filed 2014-03-11 | ||
| 2012-06-30 | $3.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $13.35M 10-Q · filed 2013-08-01 | $37.45M derived: sum of 3 quarters · filed 2014-03-11 | $51.75M derived: sum of 4 quarters · filed 2014-03-11 | ||
| 2012-03-31 | $9.65M 10-Q · filed 2013-04-30 | $33.75M derived: sum of 2 quarters · filed 2014-03-11 | $48.05M derived: sum of 3 quarters · filed 2014-03-11 | $59.05M derived: sum of 4 quarters · filed 2014-03-11 | ||
| 2011-12-31 | $24.10M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-11 | $38.40M derived: sum of 2 quarters · filed 2014-03-11 | $49.40M derived: sum of 3 quarters · filed 2014-03-11 | $60.74M 10-K · filed 2014-03-11 | ||
| 2011-09-30 | $14.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $25.30M derived: sum of 2 quarters · filed 2012-11-06 | $36.64M 10-Q · filed 2012-11-06 | |||
| 2011-06-30 | $11.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $22.34M 10-Q · filed 2012-08-02 | ||||
| 2011-03-31 | $11.34M 10-Q · filed 2012-05-03 | |||||
| 2010-12-31 | $17.25M 10-K · filed 2013-03-14 | |||||
| 2009-12-31 | $60.81M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |